About
Diagnostics & Therapeutics for Alzheimer's
Areas of Focus
Categories
DiagnosticsSmall Molecule PharmaceuticalMidwest
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
2,098
By Phase
NA: 1PHASE1: 1
By Status
COMPLETED: 2NOT_YET_RECRUITING: 1RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06856681Lead Sponsor
Clinical Utility of Early Vs. Late Blood Biomarker Testing for Alzheimer's Disease
NANot yet recruiting
800 participants
Started: Jul 31, 2025 · Completed: Mar 31, 2028
NCT07041450Collaborator
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
N/ARecruiting
500 participants
Started: Mar 14, 2025 · Completed: Mar 14, 2026
NCT06025877Lead Sponsor
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
N/AActive, not recruiting
400 participants
Started: Nov 15, 2023 · Completed: Apr 30, 2025
NCT05477056Lead Sponsor
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
N/ACompleted
366 participants
Started: Mar 1, 2021 · Completed: Oct 6, 2022
NCT02494024Lead Sponsor
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
PHASE1Completed
32 participants
Started: Jul 31, 2015 · Completed: Aug 31, 2016
Locations (1)
Headquarters
St. Louis, MO, United States
Map
Loading map...